Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer
- Deep expertise in leading drug discovery programs across oncology, neuroscience and epigenetics
- Will drive advancement of Curve’s rich pipeline of first-in-class therapeutic assets
- Builds on recent leadership team appointments, including Andre Hoekema as Chair of the Board
Southampton, UK, 9 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the appointment of Rab Prinjha, PhD, as Chief Research and Development (R&D) Officer. This continues Curve’s strong momentum expanding its leadership team following the recent appointments of Andre Hoekema and Cora Griffin, joining as Chair of the Board and Head of Business Development respectively.
